This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.
Here is a sample of this item:
by Stockwatch Business Reporter
The TSX Venture Exchange
inched up a fraction to 538.37 Thursday, ending the month down 20.31 points. Charalambos (Harry) Katevatis has filed a preliminary prospectus to list his second capital pool shell,
Zenith Capital Corp., with a $200,000 initial public offering at 10 cents. Its IPO agent is Canaccord Genuity Corp.
(There is another reporting issuer with exactly the same name. It is Donald McCaffrey's privately held Zenith Capital Corp. This company's wholly owned subsidiary, Zenith Epigenetics Ltd., is conducting clinical trials on a potential cancer treatment. Mr. McCaffrey also has a publicly held biotech company, Resverlogix Corp. (RVX: $1.19), which trades on the Toronto Stock Exchange.)
Mr. Katevatis's Zenith Capital sold two million escrow shares in April at the typically discounted price of five cents. Mr. Katevatis, 78,
bought one million of the escrow shares. Also in April, his capital pool shell sold 500,000 non-escrow shares at the IPO price of 10 cents.
The remainder is available to Stockwatch subscribers.
© 2020 Canjex Publishing Ltd. All rights reserved.